Thus, detailed investigation of CD109 concentration in serum of normal individuals and cancer patients is required, and specific tools for detecting tumor-derived CD109 by eliminating normal tissue-derived CD109 would be quite useful for application of CD109 as a tumor marker. This evidence concerns the gene CD109 and cancer.